Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Dental Procedures in Patients with Atrial Fibrillation and New Oral Anticoagulants
Author(s): Pepie Tsolka Added: 3 years ago
Novel oral anticoagulants (NOACs) represent new options for preventing stroke in patients with atrial fibrillation (AF), and have been approved for use in North America and Europe. They carry a 50 % lower risk of intracranial haemorrhage compared with warfarin, no clear interactions with food, fewer interactions with medications and no need for frequent laboratory monitoring and dose adjustments… View more

Electrophysiology & Arrhythmia
Author(s): Katrina Mountfort Added: 3 years ago
New oral anticoagulants (NOACs), including dabigatran1 (a direct thrombin inhibitor), apixaban,2 rivaroxaban3 and edoxaban4 (activated factor Xa inhibitors, not yet approved) have become alternatives to vitamin K antagonists (VKAs) for thromboembolic prevention in patients with non-valvular atrial fibrillation (AF), as a result of their numerous clinical advantages. However, there is a need for a… View more

Anticoagulation

Standards & Guidelines
Author(s): Demosthenes G Katritsis Added: 3 years ago
Reviewing recent literature of advances in arrhythmia therapy, I have found most interesting the emergence of antidotes, both general and specific, for the non-vitamin K antagonist oral anticoagulants (NOACs). NOACs offer a relative 50 % reduction in the risk of intracranial haemorrhage and haemorrhagic stroke compared with warfarin that is also maintained in the elderly. There are no clear… View more

Electrophysiology & Arrhythmia
Optimal Anticoagulation Strategy for Cardioversion in Atrial Fibrillation
Author(s): Philipp Bushoven , Sven Linzbach , Mate Vamos , et al Added: 3 years ago
Atrial Fibrillation, Cardioversion and Stroke Risk Atrial fibrillation (AF) is the most common serious chronic heart rhythm disorder with an estimated prevalence in the general population of around 1%.1 The arrhythmia affects about 2.2 million persons in the US and 4.5 million individuals in the EU. Due to the advancing age of the population, the prevalence of AF is likely to increase even… View more

Anticoagulation

Electrophysiology & Arrhythmia
How to Choose Between NOACs
Author(s): Marco Alings Added: 8 years ago

Electrophysiology & Arrhythmia
NOAC Treatment in Chronic Renal Impairment
Author(s): Jean-Yves Le Heuzey Added: 8 years ago

Electrophysiology & Arrhythmia
Once or Twice-daily NOAC Therapy – Theory and Practice
Author(s): A John Camm Added: 8 years ago

Electrophysiology & Arrhythmia
Spot Checks or Monitoring of NOACs for Anticoagulation Status
Author(s): Freek WA Verheugt Added: 8 years ago

Electrophysiology & Arrhythmia
Antidotes or Reversibility Agents – Are they Needed?
Author(s): A John Camm Added: 8 years ago

Electrophysiology & Arrhythmia
NOACs and Dual Antiplatelet Therapy
Author(s): Raffaele De Caterina Added: 8 years ago

Electrophysiology & Arrhythmia